| Gene symbol | GH1 | Synonyms | GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B, IGHD2, hGH-N | Type of gene | protein-coding | |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | Entrez:2688 MIM:139250 HGNC:HGNC:4261 Ensembl:ENSG00000259384 AllianceGenome:HGNC:4261 | |
| Description | growth hormone 1 | |||||
| Gene symbol | LIPF | Synonyms | GL, HGL, HLAL | Type of gene | protein-coding | |
| Chromosome | 10 | Map location | 10q23.31 | dbXrefs | Entrez:8513 MIM:601980 HGNC:HGNC:6622 Ensembl:ENSG00000182333 AllianceGenome:HGNC:6622 | |
| Description | lipase F, gastric type | |||||
| Gene symbol | UL128 | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_006273.2 | dbXrefs | Entrez:3077505 - | |
| Description | contains signal peptide; similar to CC chemokines; complexed with envelope glycoproteins H and L; essential in non-fibroblast cells; involved in cell entry | |||||
| Gene symbol | UL130 | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_006273.2 (176984..177628, complement) | dbXrefs | Entrez:3077481 - | |
| Description | envelope glycoprotein UL130 | |||||
| Gene symbol | UL131A | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_006273.2 (177649..178146, complement) | dbXrefs | Entrez:3077493 - | |
| Description | envelope protein UL131A | |||||
| GTO ID | GTC2289 |
| Trial ID | NCT04232280 |
| Disease | Human Cytomegalovirus Infection |
| Altered gene | gB|gH|gL|UL128|UL130|UL131A |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1647 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults |
| Year | 2020 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1647-P202 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1647 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||